STAT October 9, 2024
Katie Palmer

FDA’s Tala Fakhouri says the agency has so far received nearly 500 submissions with AI components

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs. But AI-derived or not, a new drug candidate still has to wind its way through the painstaking clinical trial process. That is why the pharma industry is also leaning into AI as a tool to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Clinical Trials, FDA, Govt Agencies, Interview / Q&A, Technology, Trends
Battle Continues Over Compounded GLP-1s
With new diversity guidance, EHR data plus AI will be critical
HLTH 2024: 4 Things That Worry FDA Commissioner Robert Califf
Recent FDA Guidance Signals Future Growth for Decentralized Clinical Trials
The Advent And Future Of Self-Administered Vaccines

Share This Article